vericiguat · Msd · NDA 214377
Verquvo
Earliest generic entry, as listed · earliest of 3 marketed strengths
26 Nov 2032
Blocked by patent: US 9604948.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9604948 | substance, product, use U-3062 | 26 Nov 2032 |
| US 10736896 | substance, product | 19 May 2031 |
| US 11439642 | use U-3062 | 19 May 2031 |
| US 8420656 | substance, product | 19 May 2031 |
| US 8921377 | use U-3062 | 19 May 2031 |
| US 9993476 | use U-3062 | 19 May 2031 |
Exclusivities · 1 unexpired
| D-198 | new dosing schedule | 21 Jan 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic tentatively approved · 214377-0018 Apr 2026
- 25 Oct 2026Generic tentatively approved · 214377-00120 Apr 2026
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214377 · 001 · RLD | tablet, oral | 2.5MG | 26 Nov 2032 |
| 214377 · 002 · RLD | tablet, oral | 5MG | 26 Nov 2032 |
| 214377 · 003 · RLD | tablet, oral | 10MG | 26 Nov 2032 |
Expired or delisted (1)
- NCE · 19 Jan 2026